



**Tuberculosis
Country Profile
2021
Democratic
People's Republic
of Korea**

Source: Global tuberculosis report 2021. Geneva: World Health Organization

Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.

Tuberculosis profile: Democratic People's Republic of Korea

Population 2020: 26 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	135 000 (116 000-155 000)	523 (451-601)
HIV-positive TB incidence		
HIV-negative TB mortality		
HIV-positive TB mortality		

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2020	66% (58-77)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	16% (10-22)

TB case notifications, 2020

Total new and relapse	89 640
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	81%
- % bacteriologically confirmed [^]	42%
- % children aged 0-14 years	5%
- % women (aged ≥15 years)	34%
- % men (aged ≥15 years)	61%
Total cases notified	98 369

TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care**, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	0%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	21%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	1 902
Patients started on treatment - MDR/RR-TB ^{^^^}	640
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	84%	95 722
Previously treated cases, excluding relapse, registered in 2019	77%	6 021
HIV-positive TB cases registered in 2019		
MDR/RR-TB cases started on second-line treatment in 2018	75%	1 487
XDR-TB cases started on second-line treatment in 2018		0

TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	95% (87-100)

TB financing

National TB budget, 2021 (US\$ millions)	47
- Funding source, domestic	13%
- Funding source, international	18%
- unfunded	69%

Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2020

(Number)




Cases attributable to five risk factors, 2020

(Number)



Total budget

(US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

[^] Calculated for pulmonary cases only

^{^^} Includes cases with unknown previous TB treatment history

^{^^^} Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed